AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02409225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
Study NCT02409225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: no Home Monitoring
Description: Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
Study NCT04121832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback training treatment in Fibromyalgia, a pilot study
Description: The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
Study NCT04121832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (treatment as usual)
Description: The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
Study NCT02325206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: one administration in the morning
Study NCT01336686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg colchicine daily for flare prophylaxis
Study NCT02325206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one administration in the morning
Study NCT02351297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: casein supplementation
Description: After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
Study NCT02351297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein supplementation
Description: After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
Study NCT02351297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin supplementation
Description: After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
Study NCT02279667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: 200 mg tablet
Study NCT02279667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: 800 mg tablet
Study NCT03754348 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: PET scan with tracer injection [18F] DPA-714
Description: the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
Study NCT03754348 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan with tracer injection [18F] DPA-714
Description: the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
Study NCT03923634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Princess® RICH
Description: Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
Study NCT00657163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: fluoxetine per os 20 mg daily
Study NCT00657163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo per os daily
Study NCT00692601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute consumption of Capsiate Natura
Description: 10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
Study NCT00692601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute consumption of Capsiate Natura
Description: 10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
Study NCT00692601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute ingestion of identical placebo capsules
Description: 10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
Study NCT04145739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
Study NCT03223506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study NCT01443676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be added to radiotherapy
Study NCT03030469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in electronic health record default for new opioid analgesic prescriptions
Study NCT01157247 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture
Study NCT01443676 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy
Study NCT01336686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: 0.6 mg colchicine daily for flare prophylaxis
Study NCT00607763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin (Mycamine)
Description: IV
Study NCT03843775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
Study NCT03843775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: encorafenib 450 mg oral QD
Study NCT01241591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 690,550 5 mg
Description: CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
Study NCT01241591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 690,550 10 mg
Description: CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
Study NCT01241591 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept 50 mg
Description: Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
Study NCT01241591 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
Study NCT03590158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRF
Description: Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
Study NCT03547921 — intervention group
Intervention type: DEVICE
Intervention: iu22 ultrasound system - phillips
Description: iu22 ultrasound system - phillips
Study NCT05174429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk-Targeted Behavioral Activation
Description: The behavioral activation component of the treatment program focused on goal setting, structuring and scheduling activities, increasing success and achievement experiences, and problem-solving. In order to maximize the impact of behavioral activation on disability reduction, goal setting and scheduling of activities focused primarily on resumption of discontinued activities as opposed to focusing on the scheduling of pleasant activities. One objective of goal setting and activity scheduling was to reduce the discrepancy between the client's pre-injury activity repertoire and the client's current activity repertoire.~Behavioral activation was supplemented by a collection of techniques designed to reduce catastrophic thinking and perceptions of injustice, two psychosocial risk factors that have been shown to contribute to prolonged work-absence.
Study NCT03315442 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Caffeine versus Energy Drink
Description: Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
Study NCT03315442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine versus Energy Drink
Description: Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
Study NCT01245829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swabbing of observation chart
Description: The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
Study NCT01245829 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Swabbing of observation chart
Description: The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
Study NCT02189928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower limb tourniquet
Description: Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations').
Study NCT02189928 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study NCT02646566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Study NCT02646566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04717323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mPAD (or TPAD) Pelvic Assist Device
Description: Gait retraining device that applies pelvic forces and measures response
Study NCT04717323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: Gait with no pelvic assistance
Study NCT01686646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol + caffeine
Description: paracetamol with caffeine
Study NCT01686646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: paracetamol
Study NCT02165930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
Study NCT02165930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
Study NCT02165930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
Study NCT01613677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT01404780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope (GVL)
Description: The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
Study NCT01404780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Direct Laryngoscope (MDL)
Description: Current standard of care at UHN for 50 years
Study NCT03701672 — intervention group
Intervention type: OTHER
Intervention: Opioid Analgesic Treatment
Description: Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
Study NCT04168229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mermaid 9 ITE
Description: A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.
Study NCT04168229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mermaid 9 BTE
Description: A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.
Study NCT00237497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
Study NCT00619658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone follow-up
Description: subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
Study NCT01226992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral
Study NCT02458794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu-Aura GainTM
Study NCT01129375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT00237497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zopiclone
Description: Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
Study NCT01226992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Transplant
Description: Fecal slurry 50 grams stool in 500ml normal saline
Study NCT00554268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-05204
Description: Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
Study NCT03143933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: I.V propofol
Study NCT03143933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT01821508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Treatment
Description: metabolic surgery for diabetes and weight control
Study NCT01821508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-En-Y gastric bypass surgery
Description: laparoscopic surgical procedure with Endoscopic Surgical Stapler
Study NCT03361566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 3 different levels of physical activity
Study NCT03361566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy intake
Description: 4 different types of energy intake
Study NCT00237497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets, orally, once daily for up to 28 nights.
Study NCT04281849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAMS-HF Program
Description: BAMS-HF Program (intervention) arm will consist of 3 in-home sessions (45-60 min ea) per week for 12 weeks with the study physical therapist. The study physical therapist will transition appropriate participants to virtual in-home visits (i.e. telerehabilitation) for some visits. The study physical therapist will design individualized exercise programs first targeting strength, then mobility and balance, and finally, aerobic capacity. Exercises will be progressive, with the goal of an 8 repetition maximum for each strength component, 80% completion rate for balance/mobility components and targeting a moderate rate of perceived exertion for aerobic components.~Interviews: There will be a recorded interview after the last session of the study to get participants' opinion of the program, suggestions for improvement and description of any barriers to participating in the program fully.
Study NCT00718809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally
Study NCT01855607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical menthol
Description: 7.5% Methylsalicylate / 2% Menthol Lotion
Study NCT01855607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo lotion
Description: The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
Study NCT01578109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Undergo BMT
Study NCT01578109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT01578109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT04271241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive stretching (PS) training
Description: PSBil and PSMono underwent 12 weeks of PS training, 3 sessions per week (36 sessions in total). In PSBil, each session lasted 40 min and included two maneuvers for both the knee extensor and plantar flexor muscles with the following protocol: 45 s elongation and 15 s recovery in the resting position, all the cycle repeated for five times 7. In PSMono, exercises were performed only on the right limb and each session had a duration of 20 min. Ctrl did not underwent any PS exercise throughout the study. To promote participants' compliance, daily classes were held at different day time (morning and afternoon) at the University Sports Centre gym. Each class was supervised by an expert operator, which monitored the attendance, the correct exercise execution and the intensity exerted during the exercise (80% of the point of discomfort). The participants not attending at least the 80% of classes were excluded from the study, and a new participant was recruited to substitute the drop out.
Study NCT02430155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bakri balloon
Description: is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
Study NCT02430155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condom loaded foley's catheter
Description: Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
Study NCT04619758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient (sunflower oil)
Description: In group A, mothers will be advised to massage their babies with sunflower oil at a dose of 10 mL/kg/day twice a day in equally divided amounts. They will be called for follow up after six months of application of sunflower oil.
Study NCT02181075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox® (LTLD)
Description: ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
Study NCT02181075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound of Target Liver Tumour
Description: Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.
Study NCT02181075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre-LTLD Biopsy of Target Liver Tumour